Genedata Screener 8 Advancing Analysis of HCS, HTS and Time Series Data Debuts at SBS 16th Annual Conference
Single Platform Empowers Screening Scientists to Deliver Results Faster with New User Interface and Improved Support for Complex Experiments
Phoenix, Ariz. – April 12, 2010 --
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced Genedata Screener® 8. Developed over the past year to address evolving customer requirements, Genedata Screener 8 delivers a refreshed and highly intuitive user interface. Additional new features improve the handling of complex experiments, and a new API pioneers flexible yet standardized data normalization. These significant advancements will broaden user adoption while helping customers accelerate the analysis of High Content Screens, High Throughput Screens, and Time Series Assays.
A mature, enterprise-level data analysis platform for all standardized screening experiments, Genedata Screener is used at leading pharmaceutical companies such as Roche and Amgen as well as forward-thinking academic and research organizations including the Broad Institute. Within a single, integrated framework, Genedata Screener manages the complete screening process from full-deck high throughput screens in hit identification to long-running compound evaluation and matrix profiling screens in lead generation and optimization. It covers all technologies relevant in plate-based screening.
Setting the Standard for Enterprise Data Analysis Platforms
Genedata Screener 8 delivers unparalleled support for complex, plate-based experiments while optimizing the visualization of data analysis for an enriched and productive user experience. New functionality includes:
Redesigned user interface (UI) can be adapted to specific needs, provides a clear view of different assays, and allows easy navigation, setup and control of assays with dozens to hundreds of read-outs for tens to thousands of plates.
New normalization API enables the configuration of specific normalization methods for the analysis of special assay types such as panel screens or pharmacological screens. These methods become centrally available, providing high flexibility while ensuring comparability of results when extending information to downstream systems.
New replicate analysis functionality for assay development and systematic quality control of confirmation screens.
“Genedata continually invests in research and development to create innovative products that will help our customers meet new challenges and technology trends in the lead discovery process,” said Dr. Othmar Pfannes, CEO of Genedata. “We have listened to our customers and believe that Genedata Screener 8 not only meets but exceeds customer expectations with superior processing speeds, optimized presentation of complex data, intuitive interactive navigation, and an outstanding user interface that makes the system very easy to use. These advanced capabilities will extend the value of Genedata Screener across departments, and help scientists and researchers realize the full potential of the richest biological data sets in a highly efficient manner.”
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead and biomarker discovery. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher®, Genedata Screener®, Genedata Expressionist®, and Genedata Analyst™ make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Japan, Germany and the US. www.genedata.com.
Marketing & Communications
Phone: +41 61 511 8459
Phone: +1 508 881 3109
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.